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Abstract
A protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing antibody (bNAb) response.
Although the development of an immunogen that elicits such antibodies remains elusive, a proportion of HIV-1 infected
individuals evolve broadly neutralizing serum responses over time, demonstrating that the human immune system can
recognize and generate NAbs to conserved epitopes on the virus. Understanding the specificities that mediate broad
neutralization will provide insight into which epitopes should be targeted for immunogen design and aid in the isolation of
broadly neutralizing monoclonal antibodies from these donors. Here, we have used a number of new and established
technologies to map the bNAb specificities in the sera of 19 donors who exhibit among the most potent cross-clade serum
neutralizing activities observed to date. The results suggest that broad and potent serum neutralization arises in most
donors through a limited number of specificities (1–2 per donor). The major targets recognized are an epitope defined by
the bNAbs PG9 and PG16 that is associated with conserved regions of the V1, V2 and V3 loops, an epitope overlapping the
CD4 binding site and possibly the coreceptor binding site, an epitope sensitive to a loss of the glycan at N332 and distinct
from that recognized by the bNAb 2G12 and an epitope sensitive to an I165A substitution. In approximately half of the
donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera.
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Introduction
The hallmark of most successful anti-viral vaccines is the ability
to induce neutralizing antibodies [1,2,3,4]. For HIV-1, NAbs have
been shown to provide protection against viral challenge in non-
human primate models [5,6,7,8,9,10,11,12,13], suggesting that a
vaccine capable of inducing similar types of antibodies would
provide benefit upon exposure to the virus. However, due to the
extraordinary genetic diversity of the HIV-1, a successful vaccine
will require the induction of antibodies that neutralize a wide
spectrum of global circulating viral isolates, i.e. broadly neutral-
izing antibodies (bNAbs) [14]. Unfortunately, the development of
an immunogen capable of eliciting bNAbs has not been met with
success to date. Importantly, although NAbs generated during
natural HIV-1 infection usually target immunodominant variable
regions of the virus, recent studies have shown that 10–30% of
infected individuals develop moderate to broadly neutralizing sera
[15,16,17,18]. These individuals are of considerable interest from
a vaccine standpoint; understanding the antibody specificities that
mediate potent cross-clade serum neutralizing activity may
illuminate potential targets for HIV-1 immunogen design. In
addition, knowledge of the epitopes targeted by the bNAbs can
assist in the design of reagents, ‘‘baits’’, to facilitate the isolation of
broadly neutralizing monoclonal antibodies (bnMAbs) from these
donors. BnMAbs can be used in molecular studies to help direct
vaccine design [19,20,21].
Several studies have previously been performed to systemati-
cally analyze the NAb specificities in HIV-1 positive sera
displaying varying degrees of neutralization breadth and potency
[15,16,17,18,22,23,24]. In all of these studies, a series of
complementary methods, such as selective removal of certain
antibody specificities using antigen-coated beads, inhibition of
neutralizing activity using linear peptides, and the use of chimeric
viruses displaying specific epitopes, were used to define the
epitopes targeted by NAbs in broadly neutralizing sera. Although
the breadth of serum neutralization could rarely be mapped
exclusively to a single epitope, several sera appeared to contain
CD4bs and co-receptor binding site (CRbs)-specific antibodies that
contributed to the overall breadth of serum neutralizing activity
[16,17,22,25]. In a minority of cases, sera were found to contain
NAbs to the membrane-proximal external region (MPER)
[16,17,23]. Arguably, one of the most significant results from
these studies was that a substantial fraction of the serum NAbs
appeared to target unidentified viral epitopes. Considering that
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monomeric gp120 and linear peptides, one possibility here is that
the serum neutralization breadth is mediated by NAbs that
recognize quaternary epitopes preferentially expressed on trimeric
Env. Two recently described broad and potent NAbs, PG9 and
PG16, fall into this category [26].
An important question that has arisen from serum studies concerns
the number of NAb specificities that mediate broad serum
neutralization. A few scenarios are possible; broad serum neutralization
could be mediated by a very large number of neutralizing antibodies
with limited breadth [27], a few relatively broad and potent
neutralizing antibody specificities, or a single, extraordinarily broad
and potent, neutralizing antibody specificity. Although these scenarios
are not mutually exclusive, the latter two are more attractive in terms of
vaccine design, as it appears far more practical to focus the immune
response on a small number of conserved epitopes with a vaccine
rather than on a large number of more variable epitopes.
In a previous study, we screened sera from approximately 1,800
HIV-1infected donorsfromThailand,Australia,theUnited Kingdom,
the United States, and several sub-Saharan African countries for
neutralizing activity and identified donors who exhibit among the most
broad and potent neutralizing serum activity observed to date [15].
The top 1% of samples screened, designated ‘‘elite neutralizers’’,
displayed particularly potent serum neutralizing activity against a cross-
clade pseudovirus panel. These donors are valuable for understanding
the development of broad responses and for the isolation of broad and
potent neutralizing monoclonal antibodies. Notably, PG9 and PG16
were isolated from an individual who ranked in the top 5% of donors
screened [26]. In this study, we have used a number of established and
new techniques to map the broadly neutralizing antibody specificities
in the serum of individuals who were ranked in the top 5% of
neutralizers identified in our previous study, including elite neutralizers.
Importantly,since many ofour approaches relyonthe use of functional
assays, we defined the epitopes recognized by the broadly neutralizing
serum antibodies in the context of the native trimer. Our results
demonstrate that the broad neutralization in the sera of most of the
individual donors can be associated with single or a small number of
specificities. Across the donor panel, broad neutralization appears
associated with 4–5 principal specificities.
Results
Serum neutralizing activity and demographics of
selected donors
A total of 19 volunteers from diverse HIV-1 epidemics were
characterized. Of the 19 volunteers, 63% were female, 26% male
and 11% unknown. The median age of all volunteers was 38 with
a median CD4 count of 414 and median log viral load of 4.07. All
volunteers were infected for at least 3 years. Of the 19 donors
analyzed, 14 ranked in the top 1% of neutralizers identified in our
previous report (elite neutralizers), and the remaining 5 ranked in
the top 5% of neutralizers. Figure S1 shows the serum
neutralization profiles of the selected donors. Serum neutralization
was assessed using an indicator cross-clade pseudovirus panel that
has previously been shown to be predictive of neutralization
breadth and potency over a larger number of isolates [15].
Recombinant gp120 and/or gp140-reactive antibodies
mediate broad serum neutralization in 70% of donors
As a first approach, we used a previously described serum
adsorption method to determine whether the NAb specificities in
these sera would react with recombinant monomeric gp120 [17].
Eighteen sera, which all neutralized HIV-1 YU2, were adsorbed
with recombinant YU2 gp120 coupled beads or blank control
beads (donor #37 was excluded from the analysis because the
plasma did not neutralize YU2). After confirming depletion
efficiencies by ELISAs, which showed that all detectable gp120-
binding antibodies had been removed (Figure S2), the adsorbed
fractions were tested for neutralizing activity against a cross-clade
pseudovirus panel (Figure 1A). For ten donors (#74, #36, #20,
#51, #26, #33, #57, #17, #14, and #23), most of the broad
serum neutralizing activity was removed after gp120 adsorption,
indicating that the serum neutralization breadth could be
attributed to gp120-reactive NAbs. In contrast, for the remaining
eight donors (#21, #30, #39, #15, #31, #24, #56, #29), a
large proportion of the broad neutralizing serum activity was
retained after removal of the YU2 gp120-specific Abs, suggesting
the presence of NAbs that recognize epitopes that are not
expressed on recombinant YU2 gp120. Based on these results, we
next sought to determine whether the NAb specificities in the
serum would react with a recombinant trimerized Env protein.
The YU2 gp140-foldon trimer was chosen for these studies
because it has been well characterized structurally and antigen-
ically [28,29,30,31,32,33], and it has been previously used for the
isolation of NAbs from HIV-1 infected patients [27]. Using the
same method as for gp120, we adsorbed the sera with YU2 gp140-
foldon coupled beads or blank control beads (Figure 1B). As
expected, we found that, if the broad neutralizing activity of a
particular serum could be adsorbed with YU2 gp120, it could also
be adsorbed with YU2 gp140. However, for a subset of donors
(#39, #21, and #15), the broad neutralizing activity of the sera
was absorbed more efficiently with YU2 gp140 than YU2 gp120.
This result may suggest that certain gp120 epitopes are better
presented on the YU2 gp140-foldon trimer. Alternatively, a
significant fraction of the serum neutralization breadth in these
donors could be mediated by NAbs directed against gp41.
Anti-MPER NAbs do not mediate a major fraction of
serum neutralization breadth and potency in the donors
studied
We next investigated the contribution of gp41-directed NAbs to
broad serum neutralizing activity. Since the MPER region of gp41
contains the epitopes recognized by three broadly neutralizing
monoclonal antibodies, 2F5, 4E10, and Z13e1, and is the only
known neutralizing determinant on gp41, we focused on
determining whether NAbs directed against this region were
mediating broad serum neutralizing activity. As a first step, we
tested the sera for neutralizing activity against a chimeric HIV-2
virus containing the complete MPER region of gp41 [24]. Based
Author Summary
The development of an immunogen that elicits antibodies
that neutralize a wide range of global circulating HIV-1
isolates is a major goal of HIV-1 vaccine research.
Unfortunately, even the most promising antibody-based
vaccine candidates have only induced NAb responses that
neutralize a limited number of these strains. However,
recent studies have demonstrated that broad and potent
NAb responses develop in the sera of a subset of HIV-1
infected individuals, and studying the nature of these
responses may provide clues for the design of new vaccine
immunogens. Here, we show that the broad neutralization
in the sera of most of the individual donors that we
studied can be associated with single or a small number of
specificities. Across the donor panel, broad neutralization
appears associated with 4–5 principal specificities.
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(Figure 2A). One of these donors (#36) also neutralized the
parental HIV-2 virus, indicating that this donor may be co-
infected with HIV-2 or contain anti-HIV-1 NAbs that cross-react
with HIV-2. Notably, since HIV-2/MPER chimeras are 1 to 2-
logs more sensitive to NAbs 4E10 and Z13e1 than HIV-1 primary
Figure 1. Serum adsorptions with recombinant Env proteins. Sera were adsorbed with YU2 gp120 or gp140-coupled beads or blank control
beads and then tested for neutralizing activity against a cross-clade pseudovirus panel using TZM-bl target cells. A) Serum neutralizing activity
depleted on YU2 gp120. B) Serum neutralizing activity depleted on YU2 gp140. Percent neutralizing activity depleted on YU2 gp120 or YU2 gp140
was calculated using the equation=(12(IC50 blank beads/IC50 antigen-coated beads))*100. Boxes are color coded as follows: Gray, 0–45%, yellow, 45–65%;
orange, 65–85%; red, 85–100%. C) Serum neutralizing activity against the selected cross-clade pseudovirus panel. Serum IC50 titers are color coded as
follows: gray squares, 1:300.IC50$1:100, yellow squares, 1:500.IC50$1:300; orange squares, 1:1500.IC50$1:500, red squares, IC50$1:1500.
doi:10.1371/journal.ppat.1001028.g001
Figure 2. Contribution of MPER-directed NAbs to broad serum neutralization. A) Sera were tested for neutralizing activity against a
chimeric HIV-2 virus containing the complete MPER region of gp41 [24]. Serum IC50 titers are expressed as 1/serum dilution. Boxes are color coded as
follows: white squares, IC50#1:80; green squares, 1:200.IC50.1:80, yellow squares, 1:500.IC50.1:200. The IC50s of anti-MPER NAbs 2F5, 4E10, Z13e1
were also determined, expressed in mg/ml. The anti-Dengue antibody Den3 is included as a negative control. B) Serum neutralizing activity after
adsorption with MPER peptide-coated beads. Sera were adsorbed with full-length MPER peptide-coated beads or blank control beads and then
tested for neutralizing activity against a cross-clade pseudovirus panel, as described previously [54]. Percent serum neutralizing activity depleted on
the MPER peptide was calculated using the equation=(12(IC50 blank beads/IC50 MPER beads))*100. C) Neutralizing activity of serum antibodies eluted
from the MPER-coated beads. Functional Abs were eluted from the MPER-coupled beads by exposing the beads to a series of increasingly acidic
conditions as described [17]. ELISA assays were used to determine the concentration of total IgG in the eluted fraction. Boxes are color coded as
follows: white squares, IC50.20 mg/ml; green squares, 20$IC50.5 mg/ml, yellow squares, 5.IC50.1 mg/ml.
doi:10.1371/journal.ppat.1001028.g002
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MPER antibodies to serum neutralization breadth and potency.
Indeed, for all six of these donors, a substantial fraction of the
broad serum neutralization could be adsorbed with monomeric
gp120, demonstrating that anti-MPER NAbs probably do not
dominate the overall serum neutralization breadth and potency.
Nonetheless, to further investigate the contribution of anti-MPER
NAbs to the serum neutralization breadth in these six donors, we
adsorbed the sera with MPER-coupled beads or blank control
beads, as described previously [23]. As above, the adsorbed sera
were then tested for neutralizing activity against a cross-clade
pseudovirus panel (Figure 2B). In addition, the MPER-specific
antibodies were eluted off the beads and tested for neutralizing
activity against the clade B isolate JR-CSF (Figure 2C). As
expected, for all six donors, the neutralizing activity of the serum
after adsorption with MPER peptide-coated beads or blank beads
were comparable, indicating that anti-MPER NAbs do not
mediate a major fraction of the serum neutralization breadth
and potency. However, for three donors, weak to moderate
neutralizing activity against JR-CSF was observed in the fraction
eluted from the MPER peptide-coupled beads, suggesting the
presence of MPER-directed NAbs at low concentrations and/or
low neutralizing potency in these sera.
CD4bs and CRbs-directed antibodies contribute to broad
serum neutralization in approximately 25% of donors
Previous serum mapping studies have evaluated CD4bs and
CRbs-directed neutralizing activity in sera by performing serum
adsorptions with gp120 point mutants that fail to react with
existing mAbs directed against these epitopes. However, a caveat
to this approach is that some CD4bs or CRbs NAbs may be
insensitive or only partially sensitive to these particular mutations.
Notably, a recently reported broadly neutralizing CD4bs-directed
NAb binds to the D368R gp120 variant, often considered a
prototypic non-CD4bs Ab binding gp120, with higher affinity
than the wild-type (WT) gp120 molecule [34]. Therefore, as an
alternative to use of the D368R gp120 variant, we developed a
serum adsorption method based on antibody competition. Using
this method, serum adsorptions to Env are performed in the
presence of saturating concentrations of a non-neutralizing
competitor mAb (the competitor Ab must be non-neutralizing
so its presence will not affect the results of the neutralization
assay). In principle, Abs directed against epitopes overlapping
that of the competitor Ab will fail to bind to the Env-coated
beads. Since the non-neutralizing CD4bs-directed mAb b6 has
been shown to compete with both CD4bs and CRbs-directed Abs
for binding to gp120 [35], b6 was used as a competitor in these
experiments.
To first validate this method, we adsorbed b12 (a CD4bs-
directed bNAb) with YU2 gp140-coated beads in the presence or
absence of saturating concentrations of b6 or blank control beads.
Indeed, all of the b12 neutralizing activity could be adsorbed with
YU2 gp140-coated beads, but none of neutralizing activity could
be adsorbed when the assay was performed in the presence of
saturating concentrations of b6 (Figure S3).
We next performed the assay using donor sera (Figure 3A). For
one donor (#23), adsorption of the broad serum neutralizing
activity with YU2 gp140 was completely inhibited by b6, suggesting
that CD4bs or CRbs NAbs dominate the serum neutralization
breadth and potency in this individual. For 4 additional donors, b6
inhibited 50–70% of broad serum neutralization indicating that
CD4bs or CRbs Abs contribute significantly to the overall serum
neutralization breadth and potency but not exclusively. For the
remaining 12 donors, none or only a small fraction of the broad
serum neutralization was blocked by b6, suggesting that CD4bs and
CRbs-directed NAbs are of minor importance to the broad
neutralizing responses in these individuals. A caveat to note is
that anti-CD4bs or anti-CRbs NAbs that mediate the serum
neutralization against some isolates (but not others) could be
present in these 12 sera, but their epitopes may not be properly
expressed in the context of YU2 gp140 used in the adsorption
experiments.
Figure 3. Analysis of CD4bs and CRbs-directed neutralizing activity. A) Sera were tested for neutralizing activity after adsorption with YU2
gp140-coupled beads in the presence or absence of saturating concentrations of mAb b6 or blank control beads. Percent gp140-directed
neutralization to the CD4bs or CRbs was calculated using the equation=[(% neutralization absorbed by gp140 beads2% neutralization absorbed by
gp140 beads in the presence of excess b6)/% neutralization absorbed by gp140 beads] *100. B) Sera were tested for neutralizing activity after
adsorption with YU2 gp120 D368R coated beads or blank control beads. Percent gp120-directed neutralization sensitive to the D368R mutation was
calculated using the equation=[(% neutralization absorbed by gp120 beads2% neutralization absorbed by gp120 D368R beads)/% neutralization
absorbed by gp120 beads] *100. Boxes are color coded as follows: Gray, 0–45%, yellow, 45–65%; orange, 65–85%; red, 85–100%.
doi:10.1371/journal.ppat.1001028.g003
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CD4bs and CRbs-directed NAbs, we also performed serum
adsorptions with a D368R gp120 variant that fails to bind CD4
and most, although not all, CD4bs-directed mAbs [25]. In two
cases, a positive correlation was observed between the b6-
inhibition adsorptions and the D368R adsorptions, indicating
that the NAbs contributing to serum neutralization breadth in
these donors are directed against the CD4bs (Figure 3B).
However, for donors #20 and #57, the NAb specificities
mediating serum neutralization breadth and potency competed
with mAb b6 for gp140 binding yet did not exhibit sensitivity to
the D368R mutation. It is possible that these NAbs are directed
against the CRbs or novel epitopes that overlap the b6 epitope.
Alternatively, these NAbs may be directed against the CD4bs but
are insensitive to the D368R substitution.
Dissecting the epitope fine specificities of serum NAbs
using a large panel of mutant pseudoviruses
The inability to adsorb a significant fraction of the broad serum
neutralization with recombinant Env proteins in approximately
one third of the donors prompted us to develop mapping strategies
based on functional assays. As a first approach, we tested all of the
sera for neutralizing activity against approximately 100 JR-CSF
pseudoviruses incorporating single amino acid substitutions
(Figure 4 and Table S1). In principle, if the serum neutralization
against JR-CSF were mediated by a small number of NAb
specificities, this activity would be diminished against pseudo-
viruses incorporating mutations that disrupt the epitopes targeted
by these bNAbs. Indeed, for approximately 75% of the donors,
potent serum neutralization against JR-CSF was abrogated by
single amino acid substitutions. Notably, for the donor from whom
PG9 and PG16 were isolated (#24), the N160K substitution in the
context of JR-CSF Env resulted in complete viral escape from
serum neutralization. Considering that this glycan is essential for
PG9 and PG16 neutralizing activity [26], but does not affect the
binding or neutralization profiles of any of the other Abs we tested
(Table S2), this result suggests that this donor’s potent serum
neutralization against JR-CSF is entirely mediated by PG9, PG16,
and similar antibodies. The N160K mutation also diminished
serum neutralization against JR-CSF in four additional donors
(#56, #29, #31, and #21), suggesting the presence of NAbs that
target epitopes overlapping that of PG9 and PG16 in these sera.
Alanine mutations in other regions of the V1/V2 and V3 loops
also abrogated serum neutralizing activity against JR-CSF in these
donors, further suggesting involvement of these regions in forming
the epitopes recognized by these NAbs. Additionally, the broad
and potent serum neutralizing activity in the five sera above could
be not be efficiently adsorbed with monomeric gp120 or
recombinantly trimerized gp140, indicating that these NAbs bind
poorly to recombinant Env proteins. However, it is worth noting
that a small number of gp120s have been identified that react
weakly with PG9 [26], suggesting that it may be possible to adsorb
these donor sera on certain gp120s.
In five different donors (#17, #51, #26, #14, #33), the N-
linked glycan at position 332 at the base of the V3 loop of gp120
was critical for potent serum neutralization against JR-CSF. Since
this glycan is also critical for 2G12 recognition [36], but does not
significantly affect the neutralization profiles of other neutralizing
mAbs we tested (Table S2), this result raised the possibility that the
donor sera target epitopes overlapping that of 2G12. Interestingly,
2G12 also requires the glycan at position 295 for neutralizing
activity, and one of the donors (#33) also exhibited sensitivity to
this mutation. The glycan-dependent nature of the epitopes
targeted by the NAbs in these sera is discussed below. Interes-
tingly, a significant fraction of the broad serum neutralizing
activity in all five of these sera could be adsorbed with monomeric
gp120 and trimeric gp140, indicating that the epitopes targeted by
these NAbs are expressed on recombinant forms of Env.
Figure 4. Effects of single amino acid substitutions on serum neutralizing activity against JR-CSF. Sera were tested for neutralizing
activity against 97 JR-CSF pseudoviruses incorporating single amino acid substitutions. Percent serum neutralizing activity sensitive to the indicated
substitution was calculated using the equation=(12(IC50 variant/IC50 WT))*100. Boxes are color coded as follows: yellow, 20–50%; orange, 50–80%; red,
80–100%. The first and second rows designate the gp120 domain and the single amino acid substitution, respectively. JR-CSF pseudovirus variants
that were similarly sensitive as wild type JR-CSF to all of the sera or variants that were globally sensitive to serum neutralization are not shown but are
listed in Table S1.
doi:10.1371/journal.ppat.1001028.g004
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sensitivity to the I165A mutation located in the V2 loop of
gp120. To gain insight into the potential epitopes targeted by these
NAbs, we tested a panel of neutralizing monoclonal antibodies for
sensitivity to this mutation. Interestingly, only the trimer-specific
NAbs 2909, 2.2G, and 2.3E required this residue for potent
neutralizing activity (Table S2). Although these NAbs are strain-
specific, they recognize quaternary epitopes involving the V2 and
V3 loops of gp120 [37,38]. For most of these donors, the broad
neutralizing activity could not be adsorbed with monomeric
gp120, suggesting that these NAbs may also target epitopes that
are preferentially expressed on trimeric HIV-1 Env. Alternatively,
the serum NAbs may target novel viral epitopes that are disrupted
by the I165A mutation.
Of note, the contribution of CD4bs-directed NAbs could not be
assessed using the mutant virus approach because pseudoviruses
incorporating mutations in this region are non-infectious. Indeed,
the donor sera identified above with CD4bs-directed neu-
tralizing activity did not exhibit significant sensitivity to any of
the pseudovirus mutants in our panel (Figure 4 and Table S1)
consistent with the critical residues that form the epitopes
recognized by these bNAb specificities being located in the CD4bs
and the corresponding variants being absent from the pseudovirus
panel. A second caveat of this assay is that certain mutations
impart global sensitivity to serum neutralization, and therefore the
effect of these residues in forming the epitopes recognized by the
broadly neutralizing specificities in the sera could not be assessed.
Interestingly, several of the substitutions that conferred a global
neutralization sensitive phenotype were located in the V2 and V3
loops and the CRbs (Table S1), suggesting that these residues play
a role in restricting antibody access to potentially neutralizing
epitopes.
A small number of antibody specificities mediate potent,
cross-clade serum neutralizing activity in individual
donors
We next investigated whether the NAb specificities that were
mediating the potent serum neutralization against JR-CSF were
also mediating the breadth of serum neutralization. Since most of
the sera exhibited sensitivity to the N160K, N332A, or I165A
mutations, we introduced these mutations into a cross-clade
pseudovirus panel and then tested the corresponding sera for
neutralization against these variants (Figure 5A). In the context of
92RW020 (clade A), the N160K mutation resulted in a loss of viral
infectivity and was therefore excluded from the N160K panel. For
all of the donors, the single amino acid substitution that
diminished serum neutralization against JR-CSF also abrogated
cross-clade serum neutralization, suggesting that the broad and
potent serum neutralization is mediated by a limited number of
antibody specificities. In a minority of cases, the serum neu-
tralizing activity against a particular isolate was not affected by the
single amino acid substitution. However, these isolates were
usually not potently neutralized by the serum (Figure 5B). For
example, for donor #24, the N160K substitution only reduced the
serum neutralizing activity against YU2 by 40%, but the serum
neutralizing titer against this isolate was at least 10-fold lower than
most of the other viruses on the panel. Thus, although there may
be several bNAb specificities in these sera, the most potent
neutralizing activity is likely only mediated by a small subset of
bNAbs.
Analysis of the glycan-dependent epitopes targeted by
the serum NAbs
We next sought to determine whether 2G12-like antibodies
were mediating the serum neutralization breadth and potency in
donors who exhibited sensitivity to the N332A mutation. Since
2G12 binding to gp120 is completely inhibited by 1M mannose
[36], we first evaluated whether high concentrations of mannose
could inhibit binding of the serum NAbs to YU2 gp140. For this,
we performed serum adsorptions in the presence of 1M mannose
or 1M glucose (negative control). As expected, 2G12 neutralizing
activity was retained after adsorption with gp120-coupled beads in
the presence of 1M mannose and depleted when the adsorption
was performed in the presence of 1M glucose (Table S3). In
contrast, the neutralization depletion efficiency of all five N332A-
sensitive sera was similar in the presence of both mannose and
glucose, indicating that the monosaccharide mannose does not
inhibit the interaction of the NAbs in the sera with YU2 gp140
(Table S3). Notably, the crystal structure of 2G12 complexed with
oligomannoses shows that 2G12 primarily recognizes the terminal
mannose on the D1 arm of Man9GlcNAc2 [39]. If the sera contain
glycan-specific NAbs that require several mannose residues for
Figure 5. Effects of single amino acid substitutions on broad serum neutralizing activity. A) Sera were tested for neutralizing activity
against a cross-clade pseudovirus panel incorporating single amino acid substitutions using a single round of replication pseudovirus assay and TZM-
bl target cells, as described previously [54]. Percent serum neutralizing activity sensitive to the indicated substitution was calculated using the
equation=(12(IC50 variant/IC50 WT))*100. Boxes are color coded as follows: green, 0–20%; yellow, 20–40%; orange, 40–80%; red, 80–100%. (—)
indicates that the isolate was neutralized by the serum at ,1:100 dilution. B) Serum neutralizing activity against the 5-pseudovirus panel. Serum IC50
titers are color coded as follows: white squares, IC50#1:100; green squares, 1:300.IC50$1:100, yellow squares, 1:500.IC50$1:300; orange squares,
1:1500.IC50$1:500, red squares, IC50$1:1500.
doi:10.1371/journal.ppat.1001028.g005
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efficiently inhibit binding of these antibodies to gp120. Therefore,
in a second approach we investigated whether the N332A-sensitive
NAbs in the sera would react with the high-mannose glycans
presented on a heavily N-glycosylated yeast protein, referred to as
TM-Pst1, that has been shown to bind 2G12 with high affinity and
inhibit 2G12 neutralization of HIV-1 pseudoviruses [40]. For
these experiments, we performed serum adsorptions with TM-
Pst1-coupled beads or blank control beads. Since all of the sera
contained TM-Pst1 binding antibodies, ELISA assays were used to
confirm depletion efficiency (data not shown). As above, we next
tested the adsorbed sera for neutralizing activity against a cross-
clade pseudovirus panel (Figure 6 and Figure S4). Interestingly, for
the donor that exhibited sensitivity to mutations at positions 295
and 332 (#33), 70–95% of the serum neutralization was adsorbed
with the TM-Pst1 protein. Furthermore, the antibodies eluted off
the beads bound to gp120, displayed cross-clade neutralizing
activity, and exhibited sensitivity to the N332A mutation (Figure
S5). Thus, it appears likely that this donor’s broad and potent
serum neutralizing activity is mediated by bNAbs that target the
oligomannose cluster on the HIV-1 glycan shield. In contrast, for
the remaining four donors, the broad neutralizing serum activity
could not be adsorbed with TM-Pst1-coupled beads. One possible
explanation is that these NAbs bind to glycan epitopes distinct
from the 2G12 epitope. Alternatively, these NAbs may bind to
protein epitopes that are conformationally dependent on the
glycan at position 332. To further examine whether any of these
sera contain anti-glycan NAbs that bind to epitopes overlapping
that of 2G12, we performed competition ELISA experiments using
biotinylated mAb 2G12 (Figure S6). None of the sera, including
the serum that could be adsorbed on the yeast TM-PstI protein,
decreased the binding of biotinylated mAb 2G12 to JR-CSF
gp120, suggesting that any glycan-specific NAbs in these sera bind
to epitopes distinct from that of 2G12.
Next, we further assessed the contribution of PG9 and PG16-like
antibodies to serum neutralization breadth and potency in donors
who exhibited sensitivity to the N160K mutation. We have
previously observed that pseudoviruses produced in cells that have
been treated with kifunensine, a mannose analogue that inhibits
type-1 endoplasmic reticulum (ER) and Golgi a-mannosidases, are
resistant to PG9 and PG16 neutralization (Doores et al., submitted).
Surprisingly,we found that other NAbs, including those that bindto
quaternary epitopes on trimeric Env, neutralized kifunensine-
treated pseudoviruses with similar potency as wild-type (WT)
pseudoviruses (Table S4). Therefore, to further investigate whether
PG9 and PG16-antibodies mediate the potent serum neutralizing
activity observed in donors who exhibit sensitivity to the N160K
mutation, we tested these sera for neutralizing activity against JR-
CSF pseudoviruses produced in the presence of kifunensine. For
comparison, we also tested sera from donors whose serum
neutralizing activity was unaffected by this mutation. Indeed, we
found that only the five sera that exhibited sensitivity to the JR-CSF
N160K mutation showed markedly diminished neutralizing activity
against kifunensine-treated JR-CSF pseudoviruses (Figure 7). To
determine whether the kifunensine-sensitive NAbs were also
mediating broad serum neutralization, we next tested these five
sera for neutralization against a cross-clade panel of pseudoviruses
produced in the presence of kifunensine. For four out of the five
donors, the broad serum neutralizing activity was almost completely
abolished against kifunensine-treated pseudoviruses (Figure 8).
Notably, for donor #29, both kifunensine treatment and the
N160Kmutation had only moderate effectsonserum neutralization
against the DU172 isolate, further suggesting a correlation between
sensitivity to the N160K mutationand kifunensine treatment.Based
Figure 6. Analysis of glycan-specific activity in sera using TM-Pst1 coated beads. Sera were tested for neutralizing activity after adsorption
with TM-Pst1-coupled beads or blank control beads. Neutralizing activity was assessed against a cross-clade pseudovirus panel using a single round
of replication pseudovirus assay using TZM-bl target cells, as described [54]. Percent neutralizing activity cross-reactive with TM-Pst1 was calculated
using the equation=(12(IC50 blank bead-adsorbed serum/IC50 Pst1-adsorbed serum))*100.
doi:10.1371/journal.ppat.1001028.g006
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antibodies mediate most of the broad and potent serum neutralizing
activity in the four donors.
Discussion
We have used several established and new approaches to map
the serum NAb specificities in 19 donors, mostly infected with
non-clade B viruses, who exhibit remarkably broad and potent
serum neutralizing activity. This study extends our previous serum
mapping studies, which only focused on a small number of patients
with relatively limited serum neutralization breadth and potency
[24]. Here, we found that the broad serum neutralizing activity in
about one third of the donors in our cohort could not be efficiently
adsorbed with recombinant monomeric gp120 or recombinantly
trimerized gp140, suggesting the possible presence of bNAbs that
Figure 7. Serum neutralization activity against kifunensine-treated JR-CSF pseudoviruses. Sera were tested for neutralizing activity
against JR-CSF pseudoviruses produced in the presence or absence of the glycosidase inhibitor kifunensine. Kifunensine-treated pseudoviruses were
produced by treating 293T cells with 25 mM kifunensine on the day of transfection. Neutralizing activity was assessed using a single round of
replication pseudovirus assay and TZM-bl target cells, as described previously [54].
doi:10.1371/journal.ppat.1001028.g007
Figure 8. Effect of kifunensine treatment on broad serum neutralization. Sera were tested for neutralizing activity against a cross-clade
panel of pseudoviruses produced in the presence or absence of the glycosidase inhibitor kifunensine. Kifunensine-treated pseudoviruses were
produced by treating 293T cells with 25 mM kifunensine on the day of transfection. Neutralizing activity was assessed using a single round of
replication pseudovirus assay and TZM-bl target cells, as described previously [54]. Percent neutralizing activity sensitive to kifunensine treatment
was calculated using the equation=(12(IC50 kifunensine treated virus/IC50 WT virus))*100. Boxes are color coded as follows: green, 0–30%; yellow, 30–60%;
orange, 60–90%; red, 90–100%.
doi:10.1371/journal.ppat.1001028.g008
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broad serum neutralizing activity was more efficiently adsorbed
with recombinantly trimerized gp140 than monomeric gp120,
indicating the presence of NAbs directed against gp120 epitopes
that are somewhat better exposed on the YU2 gp140-foldon
trimer or that the NAbs are directed against gp41. A caveat
associated with these conclusions is that a single Env protein was
used for the serum adsorption studies; it is possible that some of the
broadly neutralizing specificities in these sera would react
differently with Env proteins derived from other isolates.
MPER-directed neutralizing activity was detected in 30% of the
donors, but these NAbs did not substantially contribute to the
overall breadth and potency observed in the sera. Indeed, the
broad and potent serum neutralizing activity for most donors in
our cohort could either be adsorbed with monomeric gp120 and/
or was abrogated by specific mutations located in gp120, further
suggesting that gp41-directed NAb specificities do not mediate the
overall serum neutralization breadth and potency in these donors.
This result is in agreement with previous serum mapping studies
that suggest NAbs directed against the MPER rarely mediate
broad and potent serum neutralization [16,17,18,22].
Previous serum mapping studies have shown that, in some
individuals, NAbs directed against the CD4bs or CRbs mediate
broad serum neutralization [16,17,25,41,42]. Furthermore, four
broadly neutralizing CD4bs-directed mAbs have been isolated
from HIV-1 infected donors [34,43,Wu et al., submitted]. To
evaluate whether CD4bs or CRbs-directed NAbs were mediating
the serum neutralization breadth and potency in these donors, we
performed serum adsorptions in the presence or absence of
saturating concentrations of the non-neutralizing CD4bs-directed
mAb b6. We found that, in 5 out of the 17 donors, a significant
proportion of the overall broad and/or potent serum neutralizing
activity was mediated by receptor binding site-directed NAbs, and
in one donor, nearly all of the broad serum neutralizing activity
could be attributed to the b6-competed fraction. In two donors,
similar results were obtained when a CD4bs-altered mutant
(D368R) was used for adsorptions, indicating that the NAbs
contributing to the serum neutralization breadth in these donors
are directed against the CD4bs.
Although serum adsorption studies provide valuable insight into
the epitopes targeted by NAbs that react with recombinant Env or
linear peptides, defining the epitopes recognized by trimer-specific
antibodies requires the use of functional assays. By testing the sera
for neutralizing activity against a large panel of JR-CSF
pseudovirus mutants incorporating single amino acid substitutions,
we were able to define the epitopes recognized by the bNAb
specificities in the context of the native trimer. Interestingly, we
found that single amino acid mutations in Env frequently
generated viruses that were far less sensitive to serum neutraliza-
tion than the wild-type JR-CSF virus. Incorporation of these single
substitutions into a cross-clade pseudovirus panel similarly
generated viruses that were far more resistant to neutralization
by certain sera than the corresponding wild-type viruses. These
findings suggest that the broad and potent serum neutralizing
activity in these donors is mediated by a limited number of
antibody specificities. Notably, for the donor from whom PG9 and
PG16 were isolated, the neutralization properties of the serum
mirrored that of PG9 and PG16. These results complement the
previous observation that PG9 and PG16 could recapitulate this
donor’s broad and potent serum neutralization against most
isolates [26]. Thus, it appears highly likely that PG9, PG16, and
related antibodies mediate this donor’s serum neutralization
breadth and potency. In the context of the single amino acid
variant viruses, it should be noted that although it is most likely
that the substitutions directly define residues involved in bNAb
binding, it is also possible that the effects are due to transmitted
effects from substitutions distant from the neutralizing epitope.
Interestingly, for 9 out of the 19 donors, the potent cross-clade
serum neutralizing activity was mediated by NAbs dependent on
specific glycans for epitope recognition. In four of these donors,
the glycan at position 160 at the base of the V2 loop was critical
for serum neutralization breadth and potency, suggesting the
presence of NAbs that target epitopes overlapping that of PG9 and
PG16. To evaluate the contribution of PG9 and PG16-like
antibodies to broad and potent serum neutralizing activity, we
used the following criteria: 1) the broad and potent serum
neutralizing activity could not be efficiently adsorbed with
recombinant Env proteins, 2) the N-linked glycan at position
160 was essential for serum neutralization breadth and potency,
and 3) the broad and potent serum neutralizing activity was
diminished against pseudoviruses produced in the presence of the
glycan processing inhibitor kifunensine. Based on these criteria,
PG9 and PG16-like NAbs were identified in approximately 21%
of the donors we studied, demonstrating that this specificity is
relatively common in donors that develop broad and potent serum
neutralization.
The I165A substitution located in the V2 loop of gp120
abrogated broad serum neutralizing activity in 4 out of the 19
donors studied. Given that the trimer-specific NAbs 2909, 2.2G,
and 2.3E require this amino acid for potent neutralizing activity,
and that the broad serum neutralizing activity in these 4 donors
could not be adsorbed with monomeric gp120, it appears highly
likely that these bNAb specificities also target epitopes preferen-
tially expressed on trimeric HIV-1 Env. Indeed, this epitope may
be linked to the epitope recognized by PG9 and PG16.
We found that the N-linked glycan at position 332 was critical
for broad and potent serum neutralizing activity in approximately
25% of donors. Considering that this N-linked glycan is also
important for formation of the 2G12 epitope, we investigated
whether 2G12-like antibodies were mediating the serum neutral-
ization breadth and potency in any of these donors. Notably, the
presence of 2G12-like antibodies in HIV-1 positive sera has also
been discussed recently by others [22,44]. In one donor, a large
fraction of the broad serum neutralizing activity cross-reacted with
a yeast glycoprotein that expresses homogenous Man8GlcNac2
carbohydrates and binds 2G12 with high affinity, suggesting the
presence of bNAbs that bind directly to the glycan shield. This
donor’s serum neutralizing activity was also dependent on the
presence of the N-linked glycan at position 295, a second N-linked
glycan required for 2G12 recognition [36]. Interestingly, the sera
from this individual did not inhibit 2G12 binding to gp120,
suggesting that this bNAb specificity may bind to a glycan epitope
distinct from that of 2G12. Considering that protein-carbohydrate
interactions are typically weak, perhaps this antibody specificity
gains the necessary avidity by cross-linking two protomers within a
trimer [45,46]. Hence, low affinity binding to monomeric gp120
may also explain the lack of competition with 2G12. Another
observation worth noting is that only a single individual in our
study was found to have bNAb specificities targeting the glycan
shield, indicating that these types of antibodies rarely mediate
serum neutralization breadth and potency. However, it has
recently been shown that 2G12 is unusually efficient in protection
relative to its neutralizing ability [9], suggesting that the glycan
shield may have advantages as a vaccine target. Thus, it will be of
interest to isolate the glycan-specific NAbs from this donor and test
their protective efficacy to determine whether this is a general
property of NAbs directed against the glycan shield. For the
remaining four donors that exhibited N332A sensitivity, adsorp-
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activity of the sera; it therefore appears likely that the NAbs
mediating serum neutralization breadth and potency in these
donors bind to protein epitopes that are conformationally
dependent on the glycan at position 332.
The observation that only a limited number of antibody
specificities mediate serum neutralization breadth and potency in
these donors contrasts with the results of a previous study by
Scheid et. al in which no single broadly neutralizing monoclonal
antibodies were isolated using single B cell sorting [27]. The
authors of that study concluded that the serum neutralization
breadth in their donors was due to the combined activity of a large
number of antibody specificities that individually display limited
breadth and potency. Indeed, this may be the case for certain
donors, particularly those with relatively weak serum neutraliza-
tion breadth and potency. However, in donors with extraordi-
narily potent serum neutralization, it appears that this activity is
usually only associated with one or a few different specificities. Of
note, serum neutralization breadth found to be mediated by a
single specificity may in fact require multiple different NAbs
circulating in the plasma that recognize overlapping targets within
the same region. For example, a number of different CD4bs-
directed NAbs may mediate broad serum neutralization in donors
where all of the serum neutralizing activity can be mapped to this
region.
In summary, the data presented here show that the unusually
potent cross-clade serum neutralizing activity observed in a
selection of donors is mediated by a small number of antibody
specificities that target conserved regions of Env to a significant
extent (Figure S7 and Figure 9). Antibodies dependent on specific
glycans for Env recognition were found to be responsible for this
activity in approximately half of the donors we studied; 21% of
these donors targeted epitopes overlapping those of PG9 and
PG16 and 25% targeted epitopes that were dependent on the
presence of an N-linked glycan at position 332. CD4bs and/or
CRbs-directed NAbs contributed to serum neutralization breadth
in 25% of donors, NAbs sensitive to the I165A substitution were
identified in 21% of donors, and MPER-directed NAbs were
present in a subset of donors but did not make a substantial
contribution to the overall serum neutralization breadth and
potency. Future studies, aimed at isolating and characterizing
broadly neutralizing monoclonal antibodies from these donors,
will be important for the molecular definition of the broadly
neutralizing epitopes recognized by the donors.
Materials and Methods
Ethics statement
After obtaining written informed consent, sera and plasma were
collected from HIV-1 infected volunteers in Rwanda, Zambia,
Figure 9. Summary of the predominant NAb specificities that mediate serum neutralization breath and potency across all donors.
Percentages were calculated using only the predominant NAb specificity identified in each donor. The ‘‘unknown’’ category includes donors for
which no predominant specificity was identified.
doi:10.1371/journal.ppat.1001028.g009
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United States. Eligible participants were age 18 or older, were
HIV-1 infected for at least 3 years prior to the day of screening,
were clinically asymptomatic, without evidence of progression to
AIDS based on WHO Stage III or IV criteria or CD4 count ,200
cells/mm3 and were not on antiretroviral therapy (ART) for at
least 1 year. The study was reviewed and approved by the
Republic of Rwanda National Ethics Committee; Emory Univer-
sity Institutional Review Board; University of Zambia Research
Ethics Committee; Charing Cross Research Ethics Committee;
UVRI Science and Ethics Committee; University of New South
Wales Research Ethics Committee; and St. Vincent’s Hospital and
Eastern Sydney Area Health Service; Kenyatta National Hospital
Ethics and Research Committee; University of Cape Town
Research Ethics Committee; International Institutional Review
Board, Mahidol University Ethics Committee; Walter Reed Army
Institute of Research (WRAIR) Institutional Review Board; Ivory
Coast Comite ´ National d’Ethique des Sciences de la Vie et de la
Sante ´ (CNESVS).
Human plasma samples
Sera and plasma were collected from a cohort of HIV-1 infected
individuals (IAVI Protocol G), as previously described [15].
Samples were heat-inactivated at 55 uC for 1 h prior to use in
neutralization assays.
Antibodies
The panel of MAbs directed to HIV-1 Env included MAb b12,
b13, and 15e, directed to epitopes overlapping the CD4bs of
gp120 [43,47]; 2G12, directed to a cluster of oligomannose
residues on gp120 [36,48]; A32, directed against an epitope
comprised of the C1/C2/C4/and CD4i domains [49]; C11,
directed against the C1 domain; F425/b4e8, directed to the V3
loop on gp120 [50]; 65, directed to the CRbs binding site of
gp120 [51]; PG9, PG16, 2.2G, 2.3E, and 2909, directed to
quaternary epitopes comprised of the V2 and V3 loops of gp120
[26,37,38]; and 2F5, 4E10, and Z13e1, directed to the gp41
MPER [48,52,53].
Pseudovirus production and neutralization assays
Pseudoviruses incorporating single alanine substitutions were
generated by transfection of 293T cells with an Env-expressing
plasmid and an Env-deficient genomic backbone plasmid
(pSG3DEnv), as described previously [54]. Pseudoviruses were
harvested 72 hours post transfection for use in neutralization
assays. Neutralizing activity was assessed using a single round of
replication pseudovirus assay and TZM-bl target cells, as
described previously [54]. A chimeric HIV-2 clone containing
the MPER of HIV-1 was derived from the parental HIV-2 7312A
clone in which the HIV-2 Env MPER sequence QKLN-
SWDVFGNWFDLASWVKYIQ was replaced by the HIV-1
MPER sequence LALDKWASLWNWFDITKWLWYIK, as
described [22]. To determine IC50 values, serial dilutions of
plasma or mAb were incubated with virus and the dose-response
curves were fitted using nonlinear regression. Serum antibody
concentrations and antigen-binding activity were determined by
ELISA, as described below.
Production of monomeric and trimeric envelope
glycoproteins
The envelope glycoproteins were expressed by transfecting the
293T cell line in serum-free medium (Invitrogen, Carlsbad, CA).
In brief, the 293T cells were seeded in T225 flasks at a density of
1610
5 cells/cm
2 and transfected with the expression plasmid
YU2gp120/pcDNA3.1(2) for monomeric gp120 or YU2gp140-
fibritin/pcDNA3.1(2) DNA for trimeric gp140 proteins. In
addition, YU2 gp140-fibritin mutants were codon optimized for
mammalian expression and synthesized (GeneArt AG, Germany).
The D368R YU2 gp120 mutant was generated by Quik change
mutagenesis (Stratagene). Four days post-transfection, cell culture
supernatants were collected, clarified, filtered and two protease
inhibitor tablets (Roche) per liter of supernatant were added to
limit proteolysis. The gp120 or gp140-containing supernatants
were stored at 4uC prior to purification. The supernatants
containing the gp120 or gp140 proteins were applied to columns
containing 10 ml of Galanthus nivalis lectin-bound agarose
(Vector Laboratories). The column was then washed sequentially
with 10 column volumes of phosphate-buffered saline (PBS)
(pH 7.4) containing 0.5 M NaCl, followed by 10 column volumes
of PBS (pH 7.4). The lectin-bound glycoproteins were eluted with
a total of 12 column volumes of elution buffer (PBS buffer
[pH 7.4] with 0.5 M methyl-D-mannopyranoside). The manno-
side-eluted glycoproteins were pooled and the protein eluates were
dialyzed against phosphate-buffered saline (PBS), pH 7.4, and
concentrated with Amicon Ultra 30,000 MWCO centrifugal filter
devices (Millipore, Bedford, MA). The purified proteins were
subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and ELISA analysis, and protein purity was verified to
approach 95% homogeneity.
Serum adsorptions
Serum adsorptions with antigen-coupled beads were performed
using tosyl-activated magnetic beads, as described previously [25].
0.5 mg of gp120 and gp140 and 2 mg of TM-Pst1 were used for
bead coupling. Two to three rounds of adsorption were performed
to ensure complete removal of antigen-specific antibodies.
Functional Abs were eluted from beads by exposing the beads to
series of increasingly acidic conditions, as described [17]. For
serum adsorptions performed in the presence of b6, gp140-
coupled beads were pre-incubated with 200 mg/ml IgG b6 for 1 h
at room temperature before adding serum. ). For adsorptions
performed in the presence of monosaccharides, sera and mAb
2G12 were pre-incubated with 1M mannose or 1M glucose for 1 h
at room temperature before adding to gp140 or gp120-coupled
beads. Serum antibody concentrations and antigen-binding
activity were determined by ELISA, as described below.
ELISA assays
Ninety-six-well ELISA plates were coated overnight at 4 uC
with 50 uL PBS containing 50 ng of goat anti-human IgG Fc
(Pierce) or 100 ng gp120, gp140, or TM-Pst1 per well. The wells
were washed four times with PBS containing 0.05% Tween 20 and
blocked with 3% BSA at room temperature for 1 h. Serial
dilutions of sera or mAb were then added to the wells, and the
plates were incubated at room temperature for 1 hour. After
washing four times, goat anti-human IgG F(ab’)2 conjugated to
alkaline phosphatase (Pierce), diluted 1:1000 in PBS containing
1% BSA and 0.025% Tween 20, was added to the wells. The plate
was incubated at room temperature for 1 h, washed four times,
and the plate was developed by adding 50 uL of alkaline
phosphatase substrate (Sigma) to 5 mL alkaline phosphatase
staining buffer (pH 9.8), according to the manufacturer’s instruc-
tions. The optical density at 405 nm was read on a microplate
reader (Molecular Devices). Antibody concentration was calculat-
ed by linear regression using a standard concentration curve of
purified IgG protein. Competition ELISAs were performed by
pre-incubating 5-fold serum dilutions (starting at a 1:25) on JR-
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and then adding a concentration of biotinylated 2G12 previously
determined to give a half-maximal binding signal. Biotinylated
2G12 was detected using alkaline phosphatase- conjugated
streptavidin (1:200 in dilution buffer; Pierce), and the plates were
developed as described above. Endpoint titers of the plasma
antibodies were defined as the last reciprocal serum dilution at
which the OD signal was greater than twofold over the
background signal.
Supporting Information
Figure S1 Serum neutralization profiles of selected donors
against a cross-clade pseudovirus panel. Sera were tested for
neutralization activity against a cross-clade pseudovirus panel
using a single round of replication pseudovirus assay and U87
target cells, as described previously [15]. Neutralization assays
were performed using four-point serum dilutions (starting at
1:100), and the values reported represent the highest dilution at
which greater than or equal to 50% neutralization was achieved
[15]. Neutralization scores have been assigned previously [15].
Donors with neutralization scores $2.5 have been designated as
elite neutralizers, which represent the top 1% of all samples
screened in the previous study. The presumed clade indicates the
most predominate subtype or circulating recombinant form
currently found within the cohorts from which the samples were
collected.
Found at: doi:10.1371/journal.ppat.1001028.s001 (0.68 MB TIF)
Figure S2 Recognition of YU2 gp120 by the flow-throughs from
YU2 gp120 and blank bead adsorptions. Bars indicate the relative
end-point antibody ELISA titers in the plasma following mixing of
the sera with beads coated with YU2 gp120 or blank beads.
Found at: doi:10.1371/journal.ppat.1001028.s002 (0.33 MB TIF)
Figure S3 Antibody b6 inhibits binding of b12 to gp140-coated
beads. The bNAb b12 was tested for neutralizing activity after
adsorption with YU2 gp140-coated beads in the presence or
absence of saturating concentrations of b6 or blank control beads.
Neutralizing activity was assessed using a single round of
replication pseudovirus assay and TZM-bl target cells, as
described [54].
Found at: doi:10.1371/journal.ppat.1001028.s003 (0.15 MB TIF)
Figure S4 TM-Pst1 reactive NAbs mediate serum neutralization
breadth and potency in one donor (#33). Sera were tested for
neutralizing activity after adsorption with TM-Pst1-coupled beads
or blank control beads. Neutralizing activity was assessed using a
single round of replication pseudovirus assay using TZM-bl target
cells, as described [54].
Found at: doi:10.1371/journal.ppat.1001028.s004 (0.49 MB TIF)
Figure S5 Characterization of TM-Pst1 reactive NAbs from
donor #33. Functional Abs were eluted from the TM-Pst1
coupled beads by exposing the beads to a series of increasingly
acidic conditions as described [17]. ELISA assays were used to
determine the concentration of total IgG in the eluted fraction. A)
Binding of the TM-Pst1 eluted Abs to JR-CSF gp120, as
determined by ELISA. B) Neutralizing activity of the TM-Pst1
eluted fraction. The TM-Pst1 eluted fraction neutralized JR-CSF
(clade B) and 92RW020 (clade A) and showed reduced
neutralizing activity against JR-CSF N332A.
Found at: doi:10.1371/journal.ppat.1001028.s005 (0.25 MB TIF)
Figure S6 Competition of N332A-sensitive sera with 2G12 for
binding to gp120. Serum dilutions were added to JR-CSF gp120-
coated ELISA wells and pre-incubated for 30 min prior to adding
a concentration of 2G12 previously determined to give a half-
maximal binding signal. Sera from HIV-negative donors were
included as negative controls.
Found at: doi:10.1371/journal.ppat.1001028.s006 (0.15 MB TIF)
Figure S7 Summary of NAb specificities that mediate serum
neutralization breadth and potency in individual donors. Colors
and symbols indicate the percentage of overall serum neutraliza-
tion breadth and potency assigned to the indicated specificity: gray
(2), 0–25%; yellow (+), 25–50%; orange (++), 50–75%; red (+++),
75–100%. Percentages represent an average of all the isolates
tested.
Found at: doi:10.1371/journal.ppat.1001028.s007 (0.24 MB TIF)
Table S1 Panel of JR-CSF pseudovirus variants. Sera were
tested for neutralizing activity against JR-CSF pseudovirus
variants incorporating single amino acid substitutions. Substitu-
tions that resulted in global sensitivity to serum neutralization are
highlighted in green.
Found at: doi:10.1371/journal.ppat.1001028.s008 (0.30 MB TIF)
Table S2 Neutralizing and binding activity of MAbs to gp120
and pseudovirus variants relative to WT.
aMAbs were tested for
binding and neutralizing activity against gp120 and pseudovirus
variants, respectively. A) All NAbs were tested against HIV-1 JR-
CSF, except for 2909, 2.2G, and 2.3E, which were tested against
HIV-1 SF162. B) ELISA binding assays were performed using
gp120 captured from viral lysates, as described [50].
c Binding and
neutralizing activity is reported as fold increase in IC50 value
relative to WT and was calculated using the equation (IC50
variant/IC50 WT). Boxes are color coded as follows: gray, 0–10
fold IC50 increase; yellow, 10–100 fold IC50 increase; red, .100
fold IC50 increase.
Found at: doi:10.1371/journal.ppat.1001028.s009 (0.31 MB TIF)
Table S3 Ability of mannose to inhibit gp140 depletion of serum
neutralizing activity. Sera were tested for neutralizing activity after
adsorption with gp140-coupled beads in the presence of 1M
mannose or 1M glucose (control). The glycan-specific bNAb 2G12
was included as a positive control. % increase in IC50 was
calculated using the equation=(12(IC50 blank beads/IC50
antigen-coated beads))*100. Boxes are color coded as follows:
Green, 0–45%, yellow, 45–65%; orange, 65–85%; red, 85–100%.
Found at: doi:10.1371/journal.ppat.1001028.s010 (0.18 MB TIF)
Table S4 Effect of kifunensine treatment on neutralization by
NAbs. NAbs were tested for neutralizing activity against
pseudoviruses treated with kifunensine. Neutralizing activity is
reported as fold increase in IC50 value relative to WT and was
calculated using the equation (IC50 variant/IC50 WT). All mAbs
were tested against HIV-1 JR-CSF, except for 2909, 2.2G, and
2.3E, which were tested against HIV-1 SF162. Boxes are color
coded as follows: gray, 0–10 fold IC50 increase; yellow, 10–100
fold IC50 increase; red, .100 fold IC50 increase.
Found at: doi:10.1371/journal.ppat.1001028.s011 (0.14 MB TIF)
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